Please ensure Javascript is enabled for purposes of website accessibility

3 "Non-Coronavirus Stocks" That Would Have Doubled Your Money Over the Last Year

By Beth McKenna - Updated May 1, 2020 at 10:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stocks of companies getting a direct tailwind from the COVID-19 pandemic aren't the only top performers in 2020 and over the last year.

"Coronavirus stocks," the stocks of companies that make products and provide services that are experiencing strong demand stemming from the COVID-19 pandemic, have been getting a ton of attention. (Indeed, like many financial writers, I recently wrote an article on the topic, outlining 8 top coronavirus stocks.)

However, some stocks that don't fall into this category have also been strong performers in recent months, as well as over the long term. For instance, you'd have more than doubled your money had you invested in these "non-coronavirus stocks" a year ago: diabetes specialists Insulet and DexCom and real estate investment trust Safehold.

Dollar bill in shape of an arrow pointing upward.

Image source: Getty Images.

Three non-coronavirus stocks: Key stats

Company

Market Cap

Forward P/E

Projected Annualized 5-Year EPS Growth*

YTD 2020 Return (Loss)

1-Year Return

10-Year Return

Insulet (PODD 0.61%) $12.6 billion 357 172% 16.7% 132% 1,350%
DexCom (DXCM -1.66%) $31 billion 155 52% 53.2% 177% 2,960%
Safehold (SAFE 4.17%) $2.9 billion 44.3 36.9% 46.9% 133% N/A

S&P 500

-- -- -- (9.3%) 0.9% 202%

Data sources: Yahoo! Finance and YCharts. Data as of April 30, 2020. P/E = price-to-earnings ratio. EPS = earnings per share. YTD = year to date. *Wall Street's consensus estimate. 

The diabetes stocks

If you're looking for a growth market in which to invest, I'd suggest the diabetes space. Unfortunately, the incidence of the disease (both type 1 and type 2) has been rising around the world. Indeed, many healthcare experts consider diabetes an epidemic in the United States and many other countries.

Two top names in the diabetes space are medical-device makers Insulet and DexCom. Insulet makes the leading tubeless insulin pump, the Omnipod, and DexCom produces a continuous glucose monitoring (CGM) system, the G6. 

In fact, these two companies are partners. In the second half of this year, Insulet plans to launch its Horizon automated insulin delivery system, which uses a DexCom CGM. Moreover, the Horizon system's insulin pump will be controlled by a smartphone. 

On Tuesday, DexCom reported its first-quarter 2020 results, which crushed Wall Street's expectations. Sales rose 44% year over year to $405.1 million, sailing by the $357.6 million analyst consensus estimate. Adjusted earnings per share (EPS) landed at $0.44, compared to the year-ago period's loss of $0.05 per share. This result demolished the consensus estimate of $0.14.

Insulet is scheduled to report first-quarter results on Thursday, May 7, after market close.

Manhattan (NYC) skyline.

Image source: Getty Images.

Safehold

Safehold is a real estate investment trust (REIT) that specializes in commercial property (but no retail) ground leases in the 25 largest markets in the U.S. It buys the land underlying commercial real estate projects, which it leases back to the owners of the structures on the land. The company uses the rental income to grow the business and pay shareholders a modest dividend, currently yielding 1.2%.

Safehold was founded in 2016 and held its initial public offering in 2017, so it's relatively small for a REIT and doesn't have much of a track record. That said, it seems worth watching.

Like most companies, Safehold expects to have some near-term pain due to the pandemic. By the end of the first quarter, deals were largely on hold across the commercial real estate market. However, management also believes the company should bounce back quickly once the dust settles a bit. Here's what CEO Jay Sugarman had to say during the April 23 first-quarter earnings call:

We continue to be engaged in conversations with customers on a number of fronts, and would expect our better price, more efficient capital to be in demand once there's more clarity about the future. We expect deals put on hold may very well come back, and that existing customers will find the opportunities to deploy capital and seek our help in capitalizing those opportunities. ...

As for the existing portfolio, all of our ground leases paid [their rent] in April. 

In the first quarter, Safehold's revenue soared 84% year over year to $40.2 million. Net income jumped 56% to $17.4 million, which translated to earnings per share coming in flat with the year-ago period at $0.36. (The number of shares outstanding increased, which is why EPS was only flat while net income rose significantly.)

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$88.24 (-1.66%) $-1.49
Insulet Corporation Stock Quote
Insulet Corporation
PODD
$264.08 (0.61%) $1.59
Safehold Inc. Stock Quote
Safehold Inc.
SAFE
$45.26 (4.17%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.